Short Interest in Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) Decreases By 86.4%

Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) was the recipient of a significant decline in short interest in the month of May. As of May 15th, there was short interest totaling 2,735 shares, a decline of 86.4% from the April 30th total of 20,045 shares. Currently, 0.5% of the company’s shares are sold short. Based on an average daily volume of 70,370 shares, the days-to-cover ratio is currently 0.0 days.

Sigyn Therapeutics Trading Down 2.6%

Shares of SIGY opened at $0.04 on Thursday. The firm has a market capitalization of $96,634.00 and a P/E ratio of -0.01. Sigyn Therapeutics has a 12-month low of $0.01 and a 12-month high of $5.00. The firm has a fifty day moving average price of $0.04 and a 200-day moving average price of $0.74.

Sigyn Therapeutics Company Profile

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.